Dual antiplatelet therapy (DAPT) combines two antiplatelet agents to decrease the risk of
thrombotic complications associated with atherosclerotic cardiovascular diseases. Emerging …

Dual antiplatelet therapy (DAPT) is recommended for patients presenting with acute
coronary syndromes and patients undergoing coronary angioplasty with drug eluting stent …

a combination of aspirin with a P2Y12 receptor inhibitor, is prescribed following coronary
stent implantation to reduce the risk for stent thrombosis and ischemic atherothrombotic …

Abstract Background Whether P2Y 12 inhibitor monotherapy (P2Y 12-I) is superior to aspirin
following DAPT discontinuation post-PCI remains to be established. Methods We updated …

Dual antiplatelet therapy (DAPT), or the combination of aspirin and an oral inhibitor of the
platelet P2Y12 receptor, is indicated in acute coronary syndromes (ACS) and after …

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 antagonist improves
cardiovascular outcomes in patients with acute coronary syndrome but at a cost of an …

Since the approval of drug-eluting stents, millions of patients have heard the mantra “make
sure you don't stop your aspirin and Plavix” from their treating clinicians. While this practice …

Introduction Real‐world, country‐specific studies of dual antiplatelet therapy (DAPT)
duration among survivors of acute coronary syndrome (ACS) are important for improving …

Objective To explore how the results from the 2014 dual antiplatelet therapy (DAPT) trial
were disseminated to the scientific community and online media. Design A a systematic …

Background This analysis aimed to evaluate the clinical impact of high bleeding risk (HBR)
on adverse events after percutaneous coronary intervention (PCI). Methods We …